Dec. 2, 2014, 9:43 AM
- In a all-stock transaction, Imprimis Pharmaceuticals (IMMY) acquires South Coast Specialty Compounding. As part of the transaction, Park signs a license agreement allowing it to immediately begin making and dispensing Imprimis' ophthalmology and urology formulations in the 13 states where it is currently licensed, including CA, NV, OR and HI.
- Park will generate almost $4M in top line revenue in 2014.
- Imprimis acquired its first pharmacy, Pharmacy Creations, LLC, in April 2014.
IMMY vs. ETF Alternatives
Other News & PR